Adcock Ingram and Aspen Pharmacare have won a share of the government's HIV/AIDS drugs contract. Picture: REUTERS/SUKREE SUKPLANG
Adcock Ingram and Aspen Pharmacare have won a share of the government's HIV/AIDS drugs contract. Picture: REUTERS/SUKREE SUKPLANG

Steven Schultz from Momentum chose Aspen Pharmacare as his stock pick of the day.

“It’s Aspen, it’s a counter that’s effectively halved in value over the past 12 months. There have been a number of reasons why, most notably debt build-up and shareholders are obviously uncomfortable with that.”

Or listen to the full audio:

Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.